Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products.
about
beta-Actin regulates platelet nitric oxide synthase 3 activity through interaction with heat shock protein 90Interaction between advanced glycation end products formation and vascular responses in femoral and coronary arteries from exercised diabetic ratsERK and Akt signaling pathways are involved in advanced glycation end product-induced autophagy in rat vascular smooth muscle cellsNitric oxide-dependent beta2-adrenergic dilatation of rat aorta is mediated through activation of both protein kinase A and AktHyperglycaemia-induced impairment of endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by intracellular methylglyoxal levels in a pathway dependent on oxidative stressCoronary microvascular dysfunction in diabetes mellitus: A review17ß-estradiol antagonizes the down-regulation of ERα/NOS-3 signaling in vascular endothelial dysfunction of female diabetic ratsEndothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation.Advanced glycation end products and oxidative stress in type 2 diabetes mellitus.Glycated albumin modulates endothelial cell thrombogenic and inflammatory responsesAge-related vascular stiffening: causes and consequences.Dietary advanced glycation end products and aging.Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice.Hyperglycemia and endothelial dysfunction in atherosclerosis: lessons from type 1 diabetes.Advanced glycation end products impair the migration, adhesion and secretion potentials of late endothelial progenitor cells.Uremic Toxicity of Advanced Glycation End Products in CKD.Glycation does not modify bovine serum albumin (BSA)-induced reduction of rat aortic relaxation: the response to glycated and nonglycated BSA is lost in metabolic syndrome.The antihypertensive effect of cysteine.The antihypertensive effect of arginine.Circulating endothelial cells and chronic kidney disease.Role of endoplasmic reticulum stress signalling in diabetic endothelial dysfunction and atherosclerosis.Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension?Inhibition of L-arginine metabolizing enzymes by L-arginine-derived advanced glycation end products.PPARβ activation restores the high glucose-induced impairment of insulin signalling in endothelial cells.Effect of PKC-β Signaling Pathway on Expression of MCP-1 and VCAM-1 in Different Cell Models in Response to Advanced Glycation End Products (AGEs).Advanced glycation end products on stored red blood cells increase endothelial reactive oxygen species generation through interaction with receptor for advanced glycation end products.Fundamental role of nitric oxide in neuritogenesis of PC12h cells.Glucagon-like peptide-1 (GLP-1) protects vascular endothelial cells against advanced glycation end products (AGEs)-induced apoptosis.Diabetes induces pulmonary artery endothelial dysfunction by NADPH oxidase induction.The AGE-RAGE Axis: Implications for Age-Associated Arterial Diseases.Tanshinone IIA inhibits AGEs-induced proliferation and migration of cultured vascular smooth muscle cells by suppressing ERK1/2 MAPK signaling.Glycation Damage: A Possible Hub for Major Pathophysiological Disorders and Aging
P2860
Q24305875-345F8178-3652-4E95-A377-D6A86A4E4937Q27322359-A47F50FB-44C0-4245-80D4-9E1ACA72FA84Q28574192-639E9E45-4EA4-4A6C-8EC0-1D8BF1E98C19Q28579286-DEB24ACC-B074-494E-86DB-A44460F622C7Q33773237-617945DB-B135-48C2-BE68-CBFC2C6F3048Q34427072-C6044575-4F16-4BDF-AEA9-F07ED8EACC8BQ34500262-85D2B0E1-9BBE-4809-9C29-2A685D079060Q34747124-E86B5EE2-892A-4E2C-A7ED-D2D449B92053Q35255473-584FF65E-FA7E-44EF-9404-5B9F37EA661EQ35337660-CC35CBF0-2747-473C-8CBB-F5C3DBAF1B66Q35409645-AE6FEA4E-E191-41E5-A081-8975E7F2394FQ35670859-AC19749F-87A2-40FD-8E05-AC4E1ED35A06Q35757153-EE1323AE-A7B7-4852-899D-7D1EDA298955Q35830289-E43F7A60-2736-4176-9164-C235295C20BEQ36112416-AB708B05-48FC-4045-8D97-CCD2BE6D0ED0Q36514906-5636F740-69D9-4FFD-8C81-49E7624EEE1BQ36724696-E19A9BA1-F4E2-4E27-B426-0A085513EA7FQ37291570-F1B95CDF-531F-48E2-BDC1-0D866CE682D1Q37309054-418A64BF-F5E3-4FCD-850C-B72276EEB1D9Q38221884-DF074580-6E2D-4961-BF44-16C48ABD26DDQ39035700-C5532FF6-7CA8-4D83-821A-E379123E7650Q39158946-45AC6039-85E5-4923-AF85-AB7DB3060962Q39366317-B264207C-91D9-4C03-8A95-133E04647877Q40630791-5C4C742A-A707-4297-B9DE-1C27EF0175B8Q41319436-09D085E0-2F0A-4E5E-82A3-C03EF619D465Q41478232-2DB61FC5-A877-4C8D-85F9-67E511D529C3Q43054869-C123E54B-D7C1-4FBF-9846-066F35640646Q43108062-BF85E756-0FE4-460A-A3E8-47BB1CDDB320Q45086457-5C2BEB20-FAB2-48E0-A721-3090B2AD3EC2Q47094524-0B507256-6150-4846-AC7E-F9065E143FC8Q49197091-7C2D765C-5756-4931-8F03-675E7302F31DQ57051319-066A7401-FC51-4E47-AC21-1F179B28DC24
P2860
Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Impairment of vascular endothe ...... vanced glycation end products.
@ast
Impairment of vascular endothe ...... vanced glycation end products.
@en
type
label
Impairment of vascular endothe ...... vanced glycation end products.
@ast
Impairment of vascular endothe ...... vanced glycation end products.
@en
prefLabel
Impairment of vascular endothe ...... vanced glycation end products.
@ast
Impairment of vascular endothe ...... vanced glycation end products.
@en
P2093
P356
P1433
P1476
Impairment of vascular endothe ...... vanced glycation end products.
@en
P2093
Albert Ferro
Daniel Ruggiero
Eva Kohner
James Ritter
Rakesh Chibber
P304
P356
10.1096/FJ.02-0490FJE
P407
P577
2003-05-08T00:00:00Z